Welcome to our dedicated page for KYNTRA BIO news (Ticker: KYNB), a resource for investors and traders seeking the latest updates and insights on KYNTRA BIO stock.
Kyntra Bio reports news around its oncology and rare disease development programs, financial results, and public-company updates. Recurring items include clinical updates for FG-3246 in metastatic castration-resistant prostate cancer, roxadustat development for anemia associated with lower-risk myelodysplastic syndromes, and work involving the FG-3180 CD46-targeted PET biomarker.
Company announcements also cover quarterly and annual results, business updates, medical and investor conference presentations, and corporate matters related to its Nasdaq-listed common stock and former FibroGen identity.
Kyntra Bio (Nasdaq: KYNB) amended and restated its royalty financing agreement with NQ Project Phoebus, L.P., cutting the maximum aggregate payments from $125 million to $65 million. In exchange, Kyntra Bio made an accelerated upfront payment of $42.6 million, bringing total payments to date to $50 million, which the company says fully returns NQ Project Phoebus’s invested capital.
Remaining payments are capped at $15 million and will be funded from 50% of revenue received from Astellas in territories excluding Japan. Once this cap is reached, the agreement terminates and Kyntra Bio retains all subsequent EVRENZO™ royalties in the Astellas territories. Separately, Kyntra Bio’s subsidiary FibroGen Europe settled about $19.2 million of obligations for approximately $0.1 million, creating a significant non-operating gain. Pro forma for the upfront payment, cash, equivalents, investments, and receivables were $53.1 million on June 30, 2026, with cash runway expected into Q4 2027.
Kyntra Bio (Nasdaq: KYNB) reported second quarter 2026 financial results and pipeline progress. Total revenue from continuing operations was $(1.5) million versus $1.3 million a year earlier. Net income from continuing operations was $12.0 million, or $2.96 per share, compared with a $13.7 million loss in 2025, primarily reflecting a $30.9 million gain on deconsolidation of a subsidiary.
As of June 30, 2026, Kyntra held $95.7 million in cash, cash equivalents, investments, and accounts receivable and expects this to fund operations into 2028. The Phase 2 monotherapy trial of FG-3246 in mCRPC continues enrolling, with interim analysis planned for 4Q 2026. The pivotal Phase 3 protocol for roxadustat in LR-MDS with high transfusion burden has been finalized, with a registrational study targeted to start in 4Q 2026, supported by additional MATTERHORN data showing improved transfusion independence versus placebo.
Kyntra Bio (Nasdaq: KYNB) will release its second quarter 2026 financial results on Thursday, August 13, 2026, after market close, and will host a conference call and webcast at 5:00 PM Eastern Time to discuss results and provide a business update.
The biopharmaceutical company focuses on oncology and rare diseases, including roxadustat for anemia in chronic kidney disease and the FG-3246 antibody-drug conjugate program for metastatic castration-resistant prostate cancer, alongside its CD46-targeted PET biomarker FG-3180.
Kyntra Bio (Nasdaq: KYNB) reported new post hoc Phase 3 MATTERHORN data for roxadustat in anemia due to lower-risk MDS. Roxadustat improved transfusion independence versus placebo, with similar benefits in ring sideroblast positive and negative disease, and higher TI rates in high transfusion burden patients. TEAEs were mostly lower grade with no new safety signals, and a pivotal Phase 3 trial is planned to start in 2H 2026 after FDA feedback.
Kyntra Bio (Nasdaq: KYNB) reported first quarter 2026 results and pipeline progress. Revenue from continuing operations was $3.7 million versus $2.7 million a year ago; net loss was $15.1 million (‑$3.74 per share) versus $16.8 million (‑$4.15).
The Phase 2 FG-3246 mCRPC trial is enrolling with interim analysis expected in 4Q 2026. Positive FG-3246 combination data with enzalutamide and biomarker insights from FG-3180 were presented. A pivotal Phase 3 trial of roxadustat in LR‑MDS is being finalized, targeting initiation in 2H 2026. Kyntra reported $100.3 million in cash and equivalents, guiding runway into 2028.
Kyntra Bio (Nasdaq: KYNB) will report first quarter 2026 financial results on Monday, May 11, 2026 after market close and host a conference call and webcast at 5:00 PM ET.
The management team will present corporate and financial updates, followed by a live Q&A; a replay will be available for a limited time on the company’s Events & Presentations page.
Kyntra Bio (Nasdaq: KYNB) will present at the 25th Annual Needham Virtual Healthcare Conference April 13-16, 2026. CEO Thane Wettig will deliver the company presentation on April 13, 2026 at 1:30 PM EDT. A live webcast and a 90-day replay will be available on the company website.
Management will be available for one-on-one meetings via Needham representative requests.
Kyntra Bio (NASDAQ: KYNB) reported Q4 and full‑year 2025 results and clinical updates on March 16, 2026. Key clinical highlights include an actively enrolling Phase 2 FG‑3246 monotherapy trial in mCRPC with interim analysis expected in 2H 2026, investigator‑sponsored combo data showing median rPFS of 7.0 months (10.1 months in a subgroup), and submission of a pivotal Phase 3 protocol for roxadustat in LR‑MDS. Financials: Q4 2025 revenue $1.3M, FY2025 revenue $6.4M, FY2025 net loss $58.2M, and $109.4M in cash, cash equivalents, investments, and accounts receivable providing runway into 2028.
Kyntra Bio (Nasdaq: KYNB) will report fourth quarter and full year 2025 financial results on Monday, March 16, 2026 after market close. Management will host a conference call and webcast the same day at 5:00 PM ET to discuss results and provide a business update.
A live Q&A follows the presentation. A replay of the webcast will be available for a limited time on Kyntra Bio’s Events & Presentations page. Phone access requires registration to receive dial-in details.
Kyntra Bio (NASDAQ: KYNB) reported positive investigator‑sponsored Phase 1b/2 data for FG-3246 plus enzalutamide in mCRPC. In 44 biomarker‑unselected patients the combination produced a composite response rate 21% overall and 40% in patients with only one prior ARPI; median rPFS was 7.0 months overall and 10.1 months for one‑prior ARPI patients. The MTD/recommended dose was 2.1 mg/kg FG-3246 with 160 mg/day enzalutamide. Higher FG-3180 PET uptake trended with PSA50 response (p=0.053). Phase 2 monotherapy interim analysis expected in 2H 2026.